Shares of Inhibikase Therapeutics rose as much as 18% on Wednesday, but finished the day 10c below the stock’s $10 IPO price. Inhibikase was scheduled to trade last month but delayed the deal.
LATEST IPOS:
Inhibikase Therapeutics (IKT) opened on December 23 at $10.67. The company had priced 1.36M shares at $10.00. The deal size was increased to 1.8M shares from 1.36M shares and the range was $10.00-$12.00. ThinkEquity acted as sole book running manager for the offering. Inhibikase uses small-molecule oral protein kinase inhibitors to treat Parkinson’s disease and the gastrointestinal issues that arise in early stages of the disease.
SPAC IPOS:
CF Acquisition Corp. IV (CFIV) opened on December 23 at $10.25. The blank check company had priced its upsized initial public offering of 45M units at $10.00 per unit. CF Acquisition Corp. IV intends to focus on industries “where its management team and founders have experience, including the financial services, healthcare, real estate services, technology and software industries.”
7GC & Co. Holdings (VIIA) opened on December 23 at $10.34. The blank check company had priced its upsized initial public offering of 20M units at $10.00 per unit. While 7GC & Co. Holdings may pursue an initial business combination target in any industry or sector, it intends to concentrate its efforts in identifying businesses in the technology industry.
To see the rest of the story click here.